抗新型冠状病毒中和抗体开发关键技术与产品特点探析

Key technologies and characteristics of products of anti-SARS-CoV-2 neutralizing antibodies

新型冠状病毒肺炎(COVID-19)的持续流行和大规模扩散给全球公共卫生安全带来极大挑战。研究人员从疫苗、小分子抗病毒药物和中和抗体等多方面开展研究,为疫情防控提供安全有效的方法。其中,中和抗体具有作用机制明确、特异性好、安全性高、便于大规模生产、可同时用于预防和治疗等优势,是最具潜力的COVID-19治疗药物之一。国内外针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)中和抗体的研发项目发展迅速。该文对抗SARS-CoV-2中和抗体产品特点及关键技术进行扼要分析,为相关研究工作提供支持。

The persistent pandemic and large-scale spread of coronavirus disease 2019(COVID-19)have posed a great challenge to global public health security. Researchers have carried out extensive studies related to vaccines,small molecule antiviral drugs and neutralizing antibodies in order to provide safe and effective means for epidemic prevention and control. Among them,the monoclonal antibody with neutralizing activity has the advantages of a clear mechanism,good specificity,good safety,easy large-scale production,and the potential to be used for prevention and treatment at the same time,so it is one of the most promising therapeutic drugs for COVID-19. Neutralizing antibodies for severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)are under high-speed development at home and abroad. This paper outlines the product characteristics and key technologies of anti-SARS-CoV-2 neutralizing antibodies in order to provide support for related research.